SI-BONE Inc. Stock News

SI-BONE (NASDAQ:SIBN) had its price objective cut by investment analysts at Truist Securities from $35.00 to $30.00 in a report issued on Tuesday, Analyst Price Targets reports. The brokerage presently has a buy rating on the stock. Truist Securities price objective indicates a potential upside of 41.24% from the companys previous close. A number of []

Needham & Company LLC reiterated their buy rating on shares of SI-BONE (NASDAQ:SIBN) in a research note issued to investors on Monday, Analyst Price Targets reports. The brokerage currently has a $32.00 price target on the stock. A number of other research analysts have also recently issued reports on the stock. Truist Securities decreased their […] The post SI-BONE (NASDAQ:SIBN) Given Buy Rating at Needham & Company LLC appeared first on ETF Daily News .

Policies clarify that only iFuse Transiliac Triangular Implants are covered, and that no other products should be used based on published clinical evidence Policies clarify that only iFuse Transiliac

Policies clarify that only iFuse Transiliac Triangular Implants are covered, and that no other products should be used based on published clinical evidence Policies clarify that only iFuse Transiliac Triangular Implants are covered, and that no other products should be used based on published clinical evidence

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have earned an average rating of Buy from the nine brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered []

Invesco Ltd. boosted its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 1,734.5% in the second quarter, HoldingsChannel reports. The fund owned 129,386 shares of the companys stock after buying an additional 122,333 shares during the quarter. Invesco Ltd.s holdings in SI-BONE were worth $4,072,000 as of its most recent SEC filing. A number of []

A number of firms have modified their ratings and price targets on shares of SI-BONE (NASDAQ: SIBN) recently: 11/23/2021 SI-BONE was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, SI-BONE Inc. is a medical device company which developed the iFuse Implant System(R) for minimally []

UBS Asset Management Americas Inc. boosted its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 63.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 18,148 shares of the companys stock after buying an additional 7,048 shares during the period. UBS Asset Management Americas Inc.s holdings in []

SI-BONE (NASDAQ:SIBN) and Beauty Health (NASDAQ:SKIN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings. Insider & Institutional Ownership 96.8% of SI-BONE shares are held by institutional investors. Comparatively, 92.9% of Beauty []

Sigyn Therapeutics (NASDAQ:SIGY) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk. Institutional & Insider Ownership 96.8% of SI-BONE shares are owned by institutional investors. 78.5% of Sigyn []

Charles Schwab Investment Management Inc. increased its position in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 6.1% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 196,450 shares of the companys stock after buying an additional 11,309 shares during the period. Charles Schwab Investment Management Inc.s holdings in SI-BONE were worth $6,183,000 as of its []

SI-BONE Inc. (NASDAQ:SIBN)s traded shares stood at 0.36 million during the last session. At the close of trading, the stocks price was $21.24, to imply a decrease of -1.48% or -$0.32 in intraday trading. The SIBN shares 52-week high remains $37.21, putting it -75.19% down since that peak but still an impressive 9.32% since price SI-BONE Inc. (NASDAQ: SIBN) Has Succeeded To Excite In 2021, The Stock Is Down -28.96% Year-To-Date Read More »

SI-BONE, Inc. (NASDAQ:SIBN) SVP Michael A. Pisetsky sold 2,030 shares of SI-BONE stock in a transaction on Tuesday, November 16th. The stock was sold at an average price of $21.47, for a total value of $43,584.10. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. SIBN stock []

SI-BONE, Inc. (NASDAQ:SIBN) SVP Michael A. Pisetsky sold 2,030 shares of the companys stock in a transaction on Tuesday, November 16th. The stock was sold at an average price of $21.47, for a total value of $43,584.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC []